BMS-986489

DRUG2 trials

Sponsors

SCRI Development Innovations, LLC, Bristol-Myers Squibb

Conditions

Limited Stage Small Cell Lung CancerSmall Cell Lung Carcinoma

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

Active, not recruitingNCT06799286

Bristol-Myers SquibbSmall Cell Lung Carcinoma

Start: 2025-05-07End: 2027-05-26Target: 10Updated: 2026-05-13

Phase 2

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

RecruitingNCT06773910

SCRI Development Innovations, LLCLimited Stage Small Cell Lung Cancer

Start: 2025-03-11End: 2032-09-01Target: 250Updated: 2026-08-17

Related Papers

TIGOS-LS, an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.

Journal of Clinical Oncology2026-05-28

TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.

Journal of Clinical Oncology2025-05-28